Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore” or “the Group”), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that it has filed an ex parte application under 28 U.S.C. § 1782 in the U.S. District Court for the Northern District of California, for leave to serve subpoenas on Complete Genomics, Inc., Innomics Inc. (formerly known as BGI Americas Corp.), MGI Americas, Inc. (“MGI”), and others in support of a lawsuit that Oxford Nanopore intends to file in the courts of England and Wales.
Oxford Nanopore anticipates bringing claims against BGI Tech Solutions Co., Ltd, BGI Group, BGI, Beijing Genomics Institute at Shenzhen, MGI Holdings Co., Limited and MGI Tech Co., Ltd in England for, inter alia, claims for breach of contractual obligations, claims for breach of common law obligations of confidence, breach of duties under the Trade Secrets (enforcement etc.) Regulations 2018, and an entitlement claim to a license of certain patents.
Additionally, while not commenting on future litigation, the Group does not believe BGI’s nanopore-based sequencing technology is able to be used in commercial products around the World without infringing or misappropriating the Group’s substantial portfolio of proprietary rights.
Source – Oxford Nanopore Technologies
Oxford Nanopore Technologies to sue BGI for patent infringement
